BIOGEN INC. (BIIB) Form 8-K — Oct 28, 2026
Biogen reported Q3 2026 total revenue of $2.8 billion, up 11% year-over-year, with its Growth Portfolio up 49% to $1.26 billion in the first full quarter including acquired Apellis products. Despite the strong topline, GAAP diluted EPS was $(0.14) versus $3.17 a year ago, driven primarily by $284 million of acquired IPR&D and milestone expense tied to the RayThera acquisition. Non-GAAP diluted EPS fell 46% to $2.62. Management raised the lower end of full-year 2026 Non-GAAP EPS guidance to $12.20-$13.00 and highlighted upcoming Phase 3 readouts for litifilimab, felzartamab, and zorevunersen over the next 12 months.
Key figures
- Revenue
- 2804000000
- Guidance
- FY2026 Non-GAAP diluted EPS raised at low end to $12.20-$13.00 from $12.00-$13.00; revenue expected up mid-single digit %
- Revenue Yoy
- 11%
- Cash Position
- 1303900000
- Shares Outstanding
- 148000000
- Net debt
- $6.4 billion
- Total assets
- $32,054.1 million
- Free cash flow
- $600 million
- Operating cash flow
- $641 million
- Acquired iprd expense
- $284 million
- Non gaaap diluted eps
- 2.62
- Gaap effective tax rate
- -128.5%
- Growth portfolio revenue
- $1.26B, +49% YoY
- Non gaap diluted eps yoy
- -46%
- Non gaap effective tax rate
- 20.0%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.